The recent OIG report on the implementation of PAMA doesn’t address that CMS has ignored congressional intent in implementing the law, ACLA said.

By applying the plasmonic patch as a final step in assay development, diagnostic test developers will be able to increase fluorescence intensity onehundred-fold.

Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.

With funding from Bill Gates and others, the Diagnostics Accelerator aims to support the development of new biomarkers for the early detection of Alzheimer's.

In June, the FDA cleared tests for a broad range of conditions, including Group B strep, systemic rheumatic disease, and chlamydial or gonococcal urogenital disease.